Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 2,963 · FY2023 2,749 · FY2024 3,804 — 3-yr total 9,516
Ivermedi (შპს ივერმედი) — wholesaler of pharmaceutical and medical goods. RMS NACE declaration 46460 (wholesale of pharmaceutical goods); bia.ge lists various medical equipment and products; gross margin ~22% on GEL 46m of FY2024 revenue, a distribution profile. An earlier description called it a private medical clinic; no filing or directory record supports that.
Group parent — controls 1 company · ownership
| Line item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|---|
| 22,095 | 21,872 | 25,140 | 31,758 | 30,671 | 26,617 | 27,245 | 23,327 | +0.8% | |
| 14,556 | 13,907 | 14,405 | 14,769 | 12,741 | 13,754 | 15,135 | 15,587 | +1.0% | |
| TOTAL ASSETS | 36,651 | 35,779 | 39,545 | 46,527 | 43,412 | 40,371 | 42,380 | 38,914 | +0.9% |
| 7,619 | 6,496 | 7,883 | 11,212 | 6,879 | 6,324 | 6,700 | 7,571 | -0.1% | |
| Total Non-Current Liabilities | 2,162 | 1,097 | 30 | 37 | 40 | 40 | 40 | 500 | -18.9% |
| TOTAL LIABILITIES | 9,781 | 7,593 | 7,913 | 11,249 | 6,919 | 6,364 | 6,740 | 8,071 | -2.7% |
| 26,870 | 28,186 | 31,632 | 35,278 | 36,493 | 34,007 | 35,640 | 30,843 | +2.0% | |
| Balance Check (Assets - L&E) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Debt analysis | |||||||||
| Total Debt | 3,259 | 2,184 | 1,111 | 37 | 40 | 40 | 40 | 598 | -21.5% |
| Cash & Equivalents | 6,525 | 8,625 | 8,025 | 8,279 | 11,666 | 10,964 | 9,464 | 9,676 | +5.8% |
| Net Debt | 3,266 | 6,441 | 6,914 | 8,242 | 11,626 | 10,924 | 9,424 | 9,078 | +15.7% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →